Let’s take a quick glance at two of the ASX listed stocks; Clinuvel Pharmaceuticals Limited (CUV) and Audinate Group Limited (AD8).
Clinuvel Pharmaceuticals Limited (ASX: CUV) is an ASX listed global biopharmaceutical company based in Melbourne, Australia. The company is focusing on treating the patients with a range of severe genetic and skin disorders with operations spanning across Europe, Switzerland, the US and Singapore. With its lead compound SCENESSE®, it aims to prevent erythropoietic protoporphyria in adult patients.
On 15th May 2019, the company announced that Mr Karen Agersborg, Non-Executive Director of the company had purchased 1,200 CLVLY ADRs at $16.78 per ADR on 7th May 2019. These are United States level 1 American Depositary Receipts (ADRs) purchased over the counter (OTC: CLVLY) which represents 1 ADR to be equal to 1 ordinary share.
In the recent March 2019 quarterly report, the company reported cash receipts of $5.89 million, jumped by a massive 126% from previous quarter’s cash receipts of $2.6 million. Net cash inflow from operating activities was reported at A$2.51 million, and the company used net cash of A$27,000 for investing activities. No activities were seen on the financing front. At the end of the quarter, the company had net cash of A$44.97 million.
Daily price chart of CUV (Source: Thomson Reuters)
The market capitalisation of the company is A$1.47 billion. The stock has 52-week high and low of A$31.75 and A$9.43, respectively. The stock closed at A$31.46, after making an intraday high of A$31.75, as on 17th May. The last one-year return of the stock is massive 146.3%, and the YTD return stands at 66.2%.
Audinate Group Limited (ASX: AD8) is precisely focused on revolutionising the professional and commercial audio. The company’s Dante audio over IP networking solution is used worldwide for live sound, public address, recording industries etc. Dante technology has replaced traditional analogue audio cables and powers products available from many audio partners globally.
On 6th May 2019, the company notified that AustralianSuper Pty Ltd, which is a substantial shareholder, had reduced its stake in the company. AustralianSuper Pty Ltd had sold a total of 605,500 shares between March 2019 to May 2019. With these transactions, the total stake of AustralianSuper Pty Ltd has reduced to 6.19% from 7.2%.
On 18th April 2019, the company released its March 2019 quarterly report and posted cash collections at A$6.3 million, up by 40 % from pcp. Strong sales led to an increase in Unaudited revenue of A$6.6 million, which is over and above the cash collections. The company received total cash of A$1.6 million from operating activities and used a total of A$1.76 million towards investing activities. It received A$7,000 from financing activities in the form of proceeds from the exercise of share options.
Daily price chart of AD8 (Source: Thomson Reuters)
The market capitalisation of the company is A$433.67 million. The stock has 52-week high and low of A$7.23 and A$2.91, respectively. The stock closed at A$7.11, after making an intraday high of A$7.23, as on 17th May. The last one-year return of the stock is massive 137.2%, and the YTD return stands at 98.6%.
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.